Aduro Biotech, Inc. (NASDAQ:ADRO) VP Blaine Templeman sold 3,557 shares of the stock in a transaction dated Wednesday, September 13th. The stock was sold at an average price of $10.99, for a total value of $39,091.43. Following the sale, the vice president now owns 65,275 shares of the company’s stock, valued at $717,372.25. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Shares of Aduro Biotech, Inc. (NASDAQ:ADRO) remained flat at $11.20 during mid-day trading on Friday. 2,170,865 shares of the stock traded hands. The firm’s market cap is $835.65 million. Aduro Biotech, Inc. has a 52-week low of $8.75 and a 52-week high of $15.52. The company’s 50-day moving average price is $11.61 and its 200-day moving average price is $10.97.

Aduro Biotech (NASDAQ:ADRO) last announced its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.02). Aduro Biotech had a negative net margin of 609.58% and a negative return on equity of 43.92%. The company had revenue of $5.90 million for the quarter, compared to analysts’ expectations of $3.98 million. During the same quarter in the prior year, the firm earned $0.03 EPS. Aduro Biotech’s quarterly revenue was down 84.9% compared to the same quarter last year. On average, analysts expect that Aduro Biotech, Inc. will post ($1.37) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This report was first published by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright and trademark law. The original version of this report can be read at https://www.dailypolitical.com/2017/09/16/blaine-templeman-sells-3557-shares-of-aduro-biotech-inc-adro-stock.html.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Schwab Charles Investment Management Inc. increased its position in shares of Aduro Biotech by 5.7% during the first quarter. Schwab Charles Investment Management Inc. now owns 145,112 shares of the biotechnology company’s stock valued at $1,560,000 after buying an additional 7,812 shares during the period. Vanguard Group Inc. increased its position in shares of Aduro Biotech by 2.1% during the first quarter. Vanguard Group Inc. now owns 2,382,916 shares of the biotechnology company’s stock valued at $25,617,000 after buying an additional 48,840 shares during the period. Piermont Capital Management Inc. purchased a new position in shares of Aduro Biotech during the first quarter valued at about $386,000. Bank of New York Mellon Corp increased its position in shares of Aduro Biotech by 3.8% during the first quarter. Bank of New York Mellon Corp now owns 148,166 shares of the biotechnology company’s stock valued at $1,593,000 after buying an additional 5,470 shares during the period. Finally, Goldman Sachs Group Inc. increased its position in shares of Aduro Biotech by 330.5% during the first quarter. Goldman Sachs Group Inc. now owns 236,721 shares of the biotechnology company’s stock valued at $2,545,000 after buying an additional 181,734 shares during the period. Institutional investors own 35.05% of the company’s stock.

ADRO has been the subject of a number of recent analyst reports. BidaskClub upgraded Aduro Biotech from a “hold” rating to a “buy” rating in a report on Tuesday, July 25th. Zacks Investment Research upgraded Aduro Biotech from a “hold” rating to a “buy” rating and set a $13.00 price target for the company in a report on Tuesday, July 4th. Cowen and Company initiated coverage on Aduro Biotech in a report on Tuesday, July 18th. They set an “outperform” rating for the company. HC Wainwright set a $18.00 price target on Aduro Biotech and gave the stock a “buy” rating in a report on Thursday, August 3rd. Finally, Canaccord Genuity set a $30.00 price target on Aduro Biotech and gave the stock a “buy” rating in a report on Thursday, August 3rd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the stock. Aduro Biotech currently has an average rating of “Buy” and an average price target of $19.00.

Aduro Biotech Company Profile

Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.

Insider Buying and Selling by Quarter for Aduro Biotech (NASDAQ:ADRO)

Receive News & Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.